Candesartan cilexetil/nifedipine

Drug Profile

Candesartan cilexetil/nifedipine

Alternative Names: BAY-98-7106; Candesartan cilexetil/nifedipine GITS; Nifedipine GITS/candesartan cilexetil; Nifedipine/candesartan-cilexetil

Latest Information Update: 04 Feb 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bayer HealthCare Pharmaceuticals
  • Class Antihypertensives; Benzimidazoles; Dihydropyridines; Heart failure therapies; Ischaemic heart disorder therapies; Small molecules; Tetrazoles
  • Mechanism of Action Angiotensin type 1 receptor antagonists; Calcium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Essential hypertension

Most Recent Events

  • 13 Dec 2016 Bayer withdrew a phase III trial prior to enrolment for Essential hypertension in Italy (NCT02047019)
  • 29 Sep 2016 Bayer completes a Phase-III trial in Essential hypertension in Italy and Germany (PO) (EudraCT2012-4857-10)
  • 03 Sep 2015 Candesartan cilexetil/nifedipine is still in phase-II development for Essential hypertension in Argentina, Brazil, Lithuania, Russia, South Africa, South Korea, Spain and Ukraine
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top